Theralase Technologies Inc. V.TLT

From Sedar

[BencrosMum]

Trends

The Company anticipates that its current level of cash and cash equivalents will be sufficient to execute its current planned expenditures for the next 18 to 24 months. This estimate assumes completion of Study II, but does not include pre-clinical research and validation of TLD-1433 used in GBM, NSCLC or viruses such as COVID-19 as it moves towards a Phase Ib study in which additional financing will be needed.

Just need to knock bladder out of the park

[enriquesuave]

Nice  like I said before get the results of the next set or even at 9 months data on first set which is in 3 months and that will be enough to get warrants excercised and bring up to $10 million extra cash to get 2 PH1 trials done.

[baystock1]

enriquesuave,  in your estimate of $10 million extra cash from the exercise of warrants are you assuming that some of the 35 cent warrants expiring aug 2024 get excercised ? Without the exercise of the 2024 warrants I only see the possibility for raising $5.5 million from the 37.5 cent and 50 cent warrants, or am I missing something: Common Share Purchase Warrants Outstanding Quantity  

[enriquesuave]

The 30 cent warrants were extended another 2 years, plus the 50 cent ones as well there another batch of 50 cent expiring in Jan 2021. About 10$ million total if I remember you are showing $8 million here plus the other batch at 50 cents about another $1.5 I think.  I'm not counting on tradeable warrants.

[enriquesuave]

Sorry you are showing $7 Million and I think there's another batch of 50's for total of maybe 8-9$. Million, not 10

[NeilPaert74]

Plenty of monies $$ to gear up production of 1433 and DFOCs, run a nationwide Keytruda sucks! commercial campaign in 2022. ;-) Assuning they keep all of the studies to cheap-O-canada and get the FDA BTD and accelerated approval. After a 1 yr CR very high %.